Disinvesture of generic’s business

0

UCB’s US specialty generics subsidiary, Kremers Urban Pharmaceuticals, will be acquired by Advent International and Avista Capital Partners, two leading private equity firms with a strong healthcare focus. As per the definitive agreement, UCB will receive US$ 1 525 million upon closing, subject to regulatory approval and other customary closing conditions. UCB plans to use sum to reduce indebtedness and increase the company’s capacity strategic investments, to further accelerate growth and strengthen its innovative medicines pipeline.

SHARE

LEAVE A REPLY

Please enter your comment!
Please enter your name here